Iodopol (Sodium Iodide (131i))

Sodium Iodide I-131 is absorbed by thyroid follicular cells via the sodium‑iodide symporter. Inside the cells, the isotope emits beta particles that destroy thyroid tissue, while gamma emissions enable external imaging. This dual action delivers localized radiation therapy and facilitates scintigraphic assessment.

The exact dose of Iodopol is determined by the prescribing physician based on the patient’s condition, thyroid size, and intended therapeutic goal. Dosing is individualized and may be expressed in megabecquerels (MBq) or millicuries (mCi) according to clinical guidelines.

Iodopol is generally contraindicated during pregnancy because the radioactive iodine can affect the developing fetus. Breastfeeding should be discontinued before treatment, as iodine can be secreted in milk and expose the infant to radiation. Consultation with a specialist is essential if use is considered.

To order Iodopol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with non‑radioactive therapies such as antithyroid drugs or surgery, Iodopol offers a non‑invasive option that delivers targeted radiation directly to thyroid tissue. It can be more convenient than repeated surgeries and provides simultaneous therapeutic and diagnostic capabilities, though it requires careful radiation safety management.

Iodopol should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Handling must follow radiation safety protocols, including the use of shielding and limiting exposure to others, especially pregnant women and children, for the period recommended by the prescriber.

Iodopol is administered orally as a single dose in capsule or liquid form, depending on the product presentation. The patient swallows the dose with water, and the medication is absorbed and concentrated by the thyroid gland. Administration is performed under medical supervision, often in a controlled clinical setting.

Serious risks include severe hypothyroidism requiring lifelong hormone replacement, radiation thyroiditis with painful swelling, bone‑marrow suppression leading to pancytopenia, and the rare possibility of secondary malignancies such as leukemia. Patients should be monitored closely for these complications after treatment.

Iodopol should be avoided in patients who are pregnant, breastfeeding, have uncontrolled severe hypothyroidism, or have a known hypersensitivity to iodine or radioactive substances. It is also contraindicated in individuals who have recently received high‑dose iodinated contrast agents or are on medications that block iodine uptake without appropriate medical guidance.